JP2018048154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018048154A5 JP2018048154A5 JP2017193945A JP2017193945A JP2018048154A5 JP 2018048154 A5 JP2018048154 A5 JP 2018048154A5 JP 2017193945 A JP2017193945 A JP 2017193945A JP 2017193945 A JP2017193945 A JP 2017193945A JP 2018048154 A5 JP2018048154 A5 JP 2018048154A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- medicament
- maleate
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 11
- 229940125904 compound 1 Drugs 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010005949 Bone cancer Diseases 0.000 claims 3
- 208000018084 Bone neoplasm Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 2
- 230000002188 osteogenic effect Effects 0.000 claims 2
- 230000000010 osteolytic effect Effects 0.000 claims 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557358P | 2011-11-08 | 2011-11-08 | |
| US61/557,358 | 2011-11-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541256A Division JP2014532766A (ja) | 2011-11-08 | 2012-11-08 | 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018048154A JP2018048154A (ja) | 2018-03-29 |
| JP2018048154A5 true JP2018048154A5 (enExample) | 2018-05-31 |
Family
ID=47179011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541256A Pending JP2014532766A (ja) | 2011-11-08 | 2012-11-08 | 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤 |
| JP2017193945A Pending JP2018048154A (ja) | 2011-11-08 | 2017-10-04 | 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541256A Pending JP2014532766A (ja) | 2011-11-08 | 2012-11-08 | 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20140323522A1 (enExample) |
| EP (1) | EP2776033A1 (enExample) |
| JP (2) | JP2014532766A (enExample) |
| KR (1) | KR20140088610A (enExample) |
| CN (1) | CN104159585A (enExample) |
| AU (2) | AU2012335737A1 (enExample) |
| BR (1) | BR112014011009A2 (enExample) |
| CA (1) | CA2854336A1 (enExample) |
| EA (1) | EA201490944A1 (enExample) |
| HK (1) | HK1202062A1 (enExample) |
| IL (1) | IL232421A0 (enExample) |
| IN (1) | IN2014CN04067A (enExample) |
| MX (1) | MX2014005458A (enExample) |
| TW (2) | TWI662962B (enExample) |
| WO (1) | WO2013070890A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| PL2621481T5 (pl) | 2010-09-27 | 2023-03-13 | Exelixis, Inc. | Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości |
| CA2826751C (en) | 2011-02-10 | 2021-05-18 | Exelixis, Inc. | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
| US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
| JP2014513129A (ja) | 2011-05-02 | 2014-05-29 | エクセリクシス， インク． | 癌および骨癌疼痛の治療方法 |
| EP2758057B1 (en) | 2011-09-22 | 2017-05-31 | Exelixis, Inc. | Method for treating osteoporosis |
| CN104395284A (zh) | 2011-10-20 | 2015-03-04 | 埃克塞里艾克西斯公司 | 制备喹啉衍生物的方法 |
| HK1207587A1 (en) * | 2012-05-02 | 2016-02-05 | Exelixis, Inc. | A dual met - vegf modulator for treating osteolytic bone metastases |
| GEP20196995B (en) | 2013-03-15 | 2019-07-25 | Inc Exelixis | Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide |
| ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| US9149471B2 (en) * | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| EP3738952A1 (en) | 2014-02-14 | 2020-11-18 | Exelixis, Inc. | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| WO2015142928A1 (en) | 2014-03-17 | 2015-09-24 | Exelixis, Inc. | Dosing of cabozantinib formulations |
| CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
| MA40386A (fr) | 2014-07-31 | 2016-02-04 | Exelixis Inc | Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci |
| EA034992B1 (ru) | 2014-08-05 | 2020-04-15 | Экселиксис, Инк. | Комбинации лекарственных средств для лечения множественной миеломы |
| CN105503717A (zh) * | 2014-09-24 | 2016-04-20 | 江苏奥赛康药业股份有限公司 | 一种苹果酸卡博替尼化合物及其药物组合物 |
| EP3442531A1 (en) | 2016-04-15 | 2019-02-20 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
| CN109496212B (zh) * | 2016-10-18 | 2020-08-14 | 北京康辰药业股份有限公司 | 一种喹啉基取代的羧酸化合物或其药学上可接受的盐、其药物组合物及应用 |
| CA3060370A1 (en) | 2017-05-26 | 2018-11-29 | Exelixis, Inc. | Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| MY210421A (en) | 2018-01-26 | 2025-09-22 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
| EP4658271A1 (en) | 2023-01-31 | 2025-12-10 | Handa Oncology, LLC | Improved cabozantinib compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| US20080200515A1 (en) | 2006-12-29 | 2008-08-21 | Tap Pharmaceutical Products Inc. | Solid state forms of enantiopure ilaprazole |
| UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| PL2621481T5 (pl) * | 2010-09-27 | 2023-03-13 | Exelixis, Inc. | Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości |
| JP2013537918A (ja) * | 2010-09-27 | 2013-10-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
-
2012
- 2012-11-08 KR KR1020147015127A patent/KR20140088610A/ko not_active Ceased
- 2012-11-08 US US14/356,927 patent/US20140323522A1/en not_active Abandoned
- 2012-11-08 HK HK15102604.7A patent/HK1202062A1/xx unknown
- 2012-11-08 CN CN201280066410.5A patent/CN104159585A/zh active Pending
- 2012-11-08 CA CA2854336A patent/CA2854336A1/en not_active Abandoned
- 2012-11-08 WO PCT/US2012/064116 patent/WO2013070890A1/en not_active Ceased
- 2012-11-08 MX MX2014005458A patent/MX2014005458A/es unknown
- 2012-11-08 TW TW101141696A patent/TWI662962B/zh active
- 2012-11-08 IN IN4067CHN2014 patent/IN2014CN04067A/en unknown
- 2012-11-08 AU AU2012335737A patent/AU2012335737A1/en not_active Abandoned
- 2012-11-08 BR BR112014011009A patent/BR112014011009A2/pt not_active IP Right Cessation
- 2012-11-08 EA EA201490944A patent/EA201490944A1/ru unknown
- 2012-11-08 TW TW106131943A patent/TW201818937A/zh unknown
- 2012-11-08 JP JP2014541256A patent/JP2014532766A/ja active Pending
- 2012-11-08 EP EP12787328.9A patent/EP2776033A1/en not_active Ceased
-
2014
- 2014-05-01 IL IL232421A patent/IL232421A0/en unknown
-
2017
- 2017-09-08 AU AU2017225103A patent/AU2017225103A1/en not_active Abandoned
- 2017-10-04 JP JP2017193945A patent/JP2018048154A/ja active Pending